Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New registry aims to uncover heart disease secrets in russia

NCT ID NCT07295613

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is creating a large database of 1400 adults and children with hypertrophic cardiomyopathy (HCM) in Russia. Researchers will track their health over time to learn how the disease progresses and affects daily life. The goal is to improve diagnosis and care for HCM patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

adult and pediatric patients with HCM

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any age * Signed informed consent form (ICF) for participation in the study, including genetic testing * Meets the criteria for HCM HCM Criteria for Probands ≥ 18 Years Based on ECHO or CMR * End-diastolic LV wall thickness ≥ 15mm in any segment of the LV HCM Criteria for Probands ≥ 18 Years with Arterial Hypertension * 1st degree of AH: The same ECHO/CMR criteria as patients without AH * 2nd and 3rd degrees of AH: * Asymmetric LV hypertrophy: the ratio of septum / LV PW ≥ 1.5 or apical HCM * If asymmetry \< 1.5, the wall thickness must be ≥ 20mm * For all patients with arterial hypertension, the presence of at least one of the following ECG changes is obligatory: * Pathological "dagger" Q wave * T-wave inversion ≥ 3mm in ≥ 2 adjacent leads * Poor R progression / QS / RV1 \> RV2 \< RV3 in V1-V4 HCM Criteria for First-degree Relatives ≥ 18 Years Based on ECHO or CMR and ECG: * End-diastolic LV wall thickness ≥ 13mm in any segment and/or ECG changes in the absence of CAD, such as (at least one of the following): * Quantitative signs of LV hypertrophy\* + repolarization changes * T wave inversions in at least 2 adjacent leads: ≥ 3mm in V3-V6, I, aVL or ≥ 5mm in II, III, aVF * Pathological Q waves (\> 25% of R) in at least 2 adjacent leads: II, III, aVF (in the absence of left anterior hemiblock) or V1-V4, or I, aVL, V5-V6 \*Presence at least one of the following: * Sokolow-Lyon index (S in V1 + R in V5 or V6) \> 35mm * R or S in limb leads ≥ 20mm * S in V1 or V2 ≥ 30mm * R in V5 or V6 ≥ 30mm HCM Criteria for Children and Adolescents \< 18 Years * End-diastolic LV wall thickness in any segment \> 2.5 standard deviations (\> 2.5 z-score) above the norms for the index gender, age and weight (or body surface area) in asymptomatic children/adolescents without a family history of HCM * End-diastolic LV wall thickness in any segment \> 2.0 standard deviations (\> 2.0 z-score) above the norms for the index gender, age and weight (or body surface area) in children/adolescents with a family history of HCM or a positive genetic test Exclusion Criteria: * Uncontrolled arterial hypertension of 2nd - 3rd degree with mild/moderate (\&lt; 20mm) or symmetric LV hypertrophy or a "normal" ECG * Hemodynamically significant congenital or acquired valve heart disease * Established diagnosis of metabolic, infiltrative, endocrine, or other diseases known as "phenocopies of HCM"

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertrophic cardiomyopathy (HCM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CGMA

    Moscow, Russia

  • Central State Medical Academy

    Moscow, Moscow Reg, 1213059, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.